SAB Biotherapeutics, Inc.
- Close
- Oct 29, 2026
- Market cap
- $294.38M
- 91.14M shares
- Filings
- 436
FY 2025−100.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+18.0% FY25 yoy
- $294.38M
- 22.2×
- —
- 1.4×
- -15.53%
- —
FY2025 figures · derived
Price
Oct 29, 2026 · Official close
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | reported | |
| FY 2024 | 2024-12-31 | $1,322,410 | reported | |
| FY 2023 | 2023-12-31 | $2,238,991 | reported | |
| FY 2022 | 2022-12-31 | $23,904,181 | reported | |
| FY 2021 | 2021-12-31 | $60,876,078 | reported | |
| FY 2020 | 2020-12-31 | $55,237,759 | reported |
Segments
Products
LineFY2022ShareChange
Grant$23.90M100%−60.7%
Grant Revenue———
Total$23.90M
Biological products, except diagnostic substances
SAB Biotherapeutics, Inc. is the 79th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
AGENAgenus Inc$114.2M10.4%2.7%$323.1MSCTXScribe Therapeutics, Inc.———$321.5MAUTLAutolus Therapeutics plc$75.4M644.9%381.4%$318.3MKYTXKyverna Therapeutics, Inc.———$317.4MOCGNOcugen, Inc.$4.4M8.8%1,537.4%$296.3M
SABSSAB Biotherapeutics, Inc. (this company)$0.0100.0%—$294.4M
IPSCCentury Therapeutics, Inc.$109.2M1,556.8%8.8%$294.2MCABACabaletta Bio, Inc.———$286.9MALLOAllogene Therapeutics, Inc.$0.0100.0%—$286.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR